IN8bio (NASDAQ:INAB) Issues Earnings Results

IN8bio (NASDAQ:INAB) released its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08), FiscalAI reports.

IN8bio Trading Down 1.0%

Shares of NASDAQ:INAB traded down $0.02 on Friday, reaching $1.89. 61,132 shares of the company traded hands, compared to its average volume of 34,135. The stock has a market capitalization of $18.47 million and a P/E ratio of -0.42. The business’s 50-day simple moving average is $2.00 and its 200 day simple moving average is $1.98. IN8bio has a 52 week low of $1.17 and a 52 week high of $7.50.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on INAB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating on shares of IN8bio in a research report on Friday. Finally, Zacks Research raised IN8bio to a “hold” rating in a research note on Thursday, January 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $4.00.

Institutional Investors Weigh In On IN8bio

Several institutional investors have recently bought and sold shares of INAB. HRT Financial LP purchased a new position in IN8bio in the 4th quarter worth approximately $34,000. Captrust Financial Advisors purchased a new stake in shares of IN8bio during the fourth quarter valued at approximately $43,000. Citadel Advisors LLC purchased a new stake in shares of IN8bio during the third quarter valued at approximately $54,000. Two Sigma Investments LP bought a new position in shares of IN8bio in the third quarter worth approximately $107,000. Finally, Franklin Resources Inc. grew its holdings in shares of IN8bio by 381.6% in the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after purchasing an additional 724,637 shares during the last quarter. 92.05% of the stock is currently owned by hedge funds and other institutional investors.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.